Stocks · Dr Reddy's vs Divi's Lab
Dr Reddy's vs Divi's Lab: global generics giant versus India's leading API and CDMO company
Branded and generic formulations in multiple geographies versus deep API manufacturing and contract development for global innovators. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Dr Reddy's Laboratories is a fully integrated global pharmaceutical company with a large US generics franchise, branded markets in India and emerging economies, and a growing biosimilars pipeline, while Divi's Laboratories is India's leading active pharmaceutical ingredient (API) manufacturer and contract development and manufacturing organisation (CDMO), specialising in making the molecules that other pharma companies put into finished drugs. As of 2026-06-18, the systematic read scores Dr. Reddy's Laboratories Limited 57 and Divi's Laboratories Limited 85 on the BazaarBaazi Crack Score, an Edge Score of 78 out of 100 to Divi's Laboratories Limited.
BazaarBaaziSource & method
The matchup, at a glanceDRREDDY 57 · DIVISLAB 85
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Dr. Reddy's Laboratories Limited
Crack Score
57 / 100Mixed
Structural edges
- Fully integrated from API to formulation to commercial gives Dr Reddy's a complete value chain and the ability to capture margins at each stage, unlike a pure API supplier.
- Biosimilars pipeline is the most significant long-term growth option; biosimilars for blockbuster biologics represent multi-billion dollar market opportunities that pure API companies cannot access.
- Branded formulation markets (India, Russia, other CIS) provide relatively stable revenue with strong pricing power and brand equity that API companies do not build.
The case for
Divi's Laboratories Limited
Crack Score
85 / 100Bullish
Structural edges
- Divi's customer base (global innovator pharma companies) provides a quality of revenue that is extremely sticky: once a pharma innovator qualifies Divi's as their API source, switching costs are high due to requalification expenses.
- CDMO relationships with innovator companies for new molecular entities (NMEs) give Divi's access to the pipeline of future innovator drugs before they reach market, locking in supply relationships for drugs that may become blockbusters.
- Asset-light formulation requirement: Divi's does not need to run a sales force or marketing organisation to sell to patients; the business operates as a B2B manufacturer, simplifying operations relative to Dr Reddy's multi-market commercial complexity.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Dr. Reddy's Laboratories Limited | Divi's Laboratories Limited | |
|---|---|---|
| Return on equity | 11.4% | 15.3% |
| Net profit margin | 12.8% | 24.3% |
| EPS growth (YoY) | -24.3% | +17.4% |
| Debt to equity | 0.21 | 0.00 |
Stored from each company's filed results, as of 2026-06-17 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Dr. Reddy's Laboratories Limited | Divi's Laboratories Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharma APIs and CDMO |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~1.1 lakh cr | ~1.8 lakh cr |
| Crack Score | 57 / 100 | 85 / 100 |
| Systematic stance | Mixed | Bullish |
| Business model and customer base | A formulations and branded generic company: Dr Reddy's formulates finished dosage drugs (tablets, injectables, patches) and sells them to patients and healthcare systems directly. Customers are retail pharmacies, hospital formularies, and regulated market distributors. | An API and CDMO company: Divi's manufactures active pharmaceutical ingredients -- the raw chemical molecules -- that its customers (global branded pharma companies) then formulate into finished drugs. Customers are multinational pharma companies, not patients directly. |
| US market exposure | The US is Dr Reddy's largest market by revenue, with a significant portfolio of approved generic drug ANDAs and a commercial team selling to US retail and hospital channels. USFDA plant compliance is a critical operational requirement and risk. | Divi's sells APIs to US pharma companies who use them in their US drugs, but Divi's itself does not have a direct US consumer-facing commercial operation. USFDA compliance for Divi's manufacturing plants is critical since US customers require USFDA-approved API sources. |
| Regulatory risk profile | Multiple USFDA-approved plants across India, with the associated inspection and warning letter risk across a larger number of facilities. Broader geographic exposure to multiple country drug regulators (EMA, CDSCO) also adds regulatory complexity. | A more concentrated facility footprint (primarily two main manufacturing sites at Visakhapatnam). A USFDA observation on either site has historically caused significant revenue risk. Divi's has maintained generally strong regulatory track record, which is a core competitive asset. |
| Innovation and pipeline | Dr Reddy's has a biosimilars pipeline (complex biologics generics) and invests in new drug innovation. The biosimilars strategy targets the large global market for generic versions of blockbuster biologic drugs as their patents expire. | Divi's innovates in process chemistry: developing more efficient, lower-cost synthetic routes for existing molecules. It is also expanding into contract development (CDMO) for new innovator drug molecules, which carries higher value and longer relationships than generic API supply. |
| Best suited to | The investor wanting fully integrated pharma exposure across US generics, branded India and emerging market formulations, and biosimilars, with high geographic and revenue diversification. | The investor seeking a purer play on India's API manufacturing advantage and the global CDMO trend (innovators outsourcing manufacturing), with a business model that is less exposed to branded drug competition and more to process chemistry excellence. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on DRREDDY and DIVISLAB.
FAQ2 reader questions · AEO-eligible
The Dr Reddy's vs Divi's Lab call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the difference between an API company and a formulation company?
An API (Active Pharmaceutical Ingredient) company manufactures the pharmacologically active chemical molecule that makes a drug work. A formulation company takes the API and combines it with excipients (inactive binders, fillers, coatings) into the final dosage form the patient consumes (tablets, capsules, injectables, patches). The API is the core chemical ingredient; the formulation is the finished product. Divi's primarily makes APIs; Dr Reddy's primarily makes finished formulations (using APIs sourced from companies like Divi's or manufactured internally). Margins and business models differ significantly: formulation companies add marketing and regulatory value; API companies add process chemistry and manufacturing efficiency.
What is a CDMO and why is it a growing opportunity for Divi's?
A CDMO (Contract Development and Manufacturing Organisation) provides development and manufacturing services for pharmaceutical companies that want to outsource the making of their drugs. This is different from a pure API supplier: a CDMO may help a pharma company develop the synthesis route for a new molecule, scale it up, and then manufacture it commercially -- all on a contract basis. Global pharma companies outsource manufacturing to CDMOs to reduce capital expenditure, access specialised chemistry capabilities, and accelerate time-to-market. India, with its cost-competitive chemistry talent and manufacturing infrastructure, is becoming a preferred CDMO destination. Divi's is investing in CDMO capabilities to move up the value chain beyond commoditised API supply into higher-margin, longer-duration development contracts.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Sun Pharma vs Cipla
Specialty-led US scale versus a balanced India and respiratory franchise
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise
Compare
HDFC Bank vs Kotak Bank
Post-merger liability scale versus a focused, capital-efficient compounder
Compare
Axis Bank vs ICICI Bank
A large-franchise turnaround versus best-in-class return and earnings quality
Compare
TCS vs Wipro
Margin and scale leadership versus a leaner, restructuring-led recovery
Compare
Infosys vs HCLTech
Guidance-led pure-services read versus a differentiated products-and-engineering mix
Compare
Sun Pharma vs Dr Reddy's
Specialty-led US scale versus a generics-and-CDMO-led global diversification
Compare
Nestle India vs Britannia
Focused multi-category brand power versus a biscuits-led margin compounder
Compare
ITC vs HUL
Conglomerate cash-and-value versus the broadest mass-market FMCG compounder
Compare
UltraTech Cement vs Grasim
The cement industry leader versus an Aditya Birla conglomerate with a cement holding and new businesses
Compare
SBI Life vs HDFC Life
Bancassurance scale through SBI versus a diversified product mix and balanced distribution
Compare
L&T vs Siemens India
A diversified domestic engineering conglomerate versus a focused industrial-technology franchise
Compare
Bajaj Auto vs Eicher Motors
Export-led volume scale and EV push versus the premium Royal Enfield franchise
Compare
DMart vs Trent
Everyday-value grocery scale versus a fast-fashion and format-expansion story
Compare
Asian Paints vs Pidilite
Decorative paint leadership versus a monopoly in construction adhesives
Compare
DLF vs Lodha
The oldest premium residential-and-commercial franchise versus the fastest-growing pan-India developer
Compare
Tata Power vs Adani Green
A diversified integrated power company versus a pure-play utility-scale renewables developer
Compare
TVS Motor vs Hero MotoCorp
A premium-and-premium-EV challenger versus the mass-market volume king
Compare
Shree Cement vs Ambuja Cements
The highest-margin, most efficient pure-play cement operator versus Adani-backed capacity scale
Compare
Cipla vs Zydus Lifesciences
A global respiratory and chronic-therapy generics leader versus an India-first FMCG-pharma blend with a biosimilar optionality
Compare
Tech Mahindra vs LTIMindtree
A telecom-anchored restructuring story versus a high-quality engineering-and-digital merger compounder
Compare
Tata Consumer vs Varun Beverages
A multi-category Tata group FMCG build-out versus the fastest-growing PepsiCo bottler franchise in the world
Compare
Adani Power vs NTPC
A private-sector capacity-growth story versus the sovereign-backed power PSU with a renewable pivot
Compare
Cholamandalam vs Shriram Finance
A diversifying vehicle and home-finance NBFC versus the dominant used-commercial-vehicle lender
Compare
Hindalco vs Vedanta
A globally integrated aluminium-and-copper compounder versus a diversified natural-resources conglomerate
Compare
Mahindra vs Hyundai India
The SUV-led domestic compounder with a farm and EV platform versus the premium Korean franchise in the Indian market
Compare
PFC vs REC Ltd
Broader power financing platform versus a focused utility lender
Compare
Bank of Baroda vs Canara Bank
Diversified PSU franchise with international presence versus a sharper domestic recovery
Compare
Wipro vs HCLTech
Turnaround execution potential versus a steadier IT services and products blend
Compare
Godrej Consumer Products vs Dabur
Personal care and home care momentum versus defensive staples and wellness breadth
Compare
IndusInd Bank vs Kotak Bank
Higher-beta recovery potential versus quality-first private banking franchise
Compare
BPCL vs GAIL India
Downstream petroleum and refining leverage versus gas transmission and utility infrastructure
Compare
Tata Steel vs JSPL
Integrated steel scale and global diversification versus a focused domestic metals execution story
Compare
Torrent Pharma vs Divi's Labs
Branded formulations franchise versus specialty API and custom manufacturing excellence
Compare
ABB India vs CG Power
Premium electrification and automation technology versus a capital goods recovery and execution story
Compare
Motherson vs Bosch India
Global multi-category auto-component scale versus premium engineering and technology in auto systems
Compare
Muthoot Finance vs Bajaj Finance
Specialist gold-backed lending versus a broad consumer and retail credit platform
Compare
Adani Energy Solutions vs Tata Power
Transmission and distribution network expansion versus an integrated utility and clean energy franchise
Compare
IRFC vs PFC
Single-borrower sovereign railway book versus a broad power-sector financing platform
Compare
Tata Capital vs Bajaj Finance
Diversified Tata-group NBFC versus India's most scaled retail lending franchise
Compare
Zydus vs Dr Reddy's
Differentiated molecule pipeline with biologics versus a scaled global generics and API platform
Compare
Mazagon Dock vs HAL
Naval shipbuilding monopoly versus aerospace manufacturing and MRO scale
Compare
Hindustan Zinc vs Vedanta
Pure zinc, lead and silver play versus a diversified global natural resources conglomerate
Compare
Cummins vs Siemens India
Engine and power generation specialist versus a diversified industrial technology and energy platform
Compare
Reliance vs Bharti Airtel
Vertically integrated conglomerate with multiple bets versus a focused telecom platform scaling into Africa and digital services
Compare
Maruti vs Tata Motors
Dominant passenger car volume leader versus a dual-play of EV transition and JLR luxury recovery
Compare
Coal India vs ONGC
Domestic monopoly coal producer versus an integrated oil and gas company exposed to global energy prices
Compare
HDFC AMC vs Jio Financial Services
Established mutual fund franchise with deep distribution versus a blank-cheque fintech backed by India's largest conglomerate
Compare
PNB vs Union Bank
NPA recovery trajectory and loan book quality improvement post the bad debt cycle
Compare
BEL vs Solar Industries
Electronics and radar systems PSU versus the private explosives and defence ammunition specialist
Compare
TCS vs Infosys
Scale and margin consistency versus vertical depth and consulting-led positioning
Compare
SBI vs HDFC Bank
Government-backed franchise with unmatched reach versus private sector quality and returns consistency
Compare
ABB vs Siemens India
Power and automation focus with a divestment-lightened portfolio versus a more diversified industrial-digital technology mix
Compare
United Spirits vs Varun Beverages
Premium Indian Made Foreign Liquor franchise versus the largest PepsiCo franchise bottler
Compare
Apollo Hospitals vs Sun Pharma
Hospital infrastructure and healthcare services platform versus a diversified global pharmaceutical company
Compare
IOC vs BPCL
India's largest oil refiner-marketer versus the privatisation candidate with an international upstream portfolio
Compare
Wipro vs Tech Mahindra
Broad-based enterprise IT versus telecom-rooted technology services with a manufacturing and 5G pivot
Compare
HCL Tech vs LTIM
Scale, products revenue, and margin consistency versus integration execution and faster revenue growth potential
Compare
Bajaj Auto vs TVS Motor
Premium motorcycle brand and export franchise versus diversified two-wheeler portfolio with aggressive EV positioning
Compare
Hindalco vs Tata Steel
Aluminium's EV and green transition tailwinds via Novelis versus steel's domestic infrastructure cycle leverage
Compare
Bajaj Finance vs Cholamandalam
Consumer lending breadth and franchise premium versus vehicle and secured lending with faster-growing aspirations
Compare
NTPC vs Adani Green Energy
Diversified power generation with a growing renewable arm versus a pure-play renewable developer with the largest India pipeline
Compare
Eicher Motors vs Hero MotoCorp
Royal Enfield's premium leisure motorcycle franchise with international aspirations versus the world's largest two-wheeler company by volume serving everyday Indian commuters
Compare
IRFC vs REC
Single-borrower sovereign certainty (Ministry of Railways) versus diversified power sector lending with RE exposure
Compare
ITC vs Tata Consumer
Cigarette cash flow-funded FMCG empire building versus a pure-play packaged foods and beverages company with global brand scale
Compare
Cipla vs Torrent Pharma
US generics and global branded portfolio versus high-margin India-branded specialty and Germany international presence
Compare
Godrej Consumer vs HUL
Indian conglomerate with emerging market FMCG ambition versus the multinational FMCG powerhouse with the deepest Indian distribution moat
Compare
Bajaj Holdings vs Bajaj Finserv
Holding company discount vs. direct operating exposure
Compare
Reliance vs Adani Enterprises
Proven cash generation vs. infrastructure incubation model
Compare
Titan vs Asian Paints
Discretionary jewellery growth vs. essential home maintenance leadership
Compare
SBI vs Axis Bank
PSU scale and dividend vs. private bank growth and ROE
Compare
Coal India vs Power Grid
Volume-driven cash flow vs. regulated asset-based return
Compare
HDFC AMC vs SBI Life
Asset management fee income vs. insurance premium compounding